-

01:52:29 PM

FENC Stock News

FENC - Fennec Pharmaceuticals Inc

09/07/23 5:59 AM

Nasdaq : FENC

conferenceslow float

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one

RHEA-AI

neutral

08/03/23 5:59 AM

Nasdaq : FENC

earningslow float

Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update

~ Growing Physician Awareness and Usage of PEDMARK ® Drove Quarterly Revenue Growth of 98% ~ ~Fennec Expands Leadership Team with the Appointment of Adrian Haigh as Chief Operating Officer ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2023

RHEA-AI

neutral

07/31/23 5:30 AM

Nasdaq : FENC

conferencesearningslow float

Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2023 financial results before the opening of the U.S.

RHEA-AI

neutral

06/12/23 5:00 PM

Nasdaq : FENC

low float

Fennec Announces Results of Annual Meeting

Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 24, 2023 (the “Circular”) for the Annual General Meeting of Shareholders were

RHEA-AI

neutral

06/06/23 5:44 AM

Nasdaq : FENC

low float

Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

Fennec Pharmaceuticals

RHEA-AI

neutral

05/11/23 6:01 AM

Nasdaq : FENC

earningslow float

Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

~ Strong PEDMARK ® Commercial Momentum Building in 2023 with Broad Payor and Medicaid Coverage ~ ~ PEDMARK ® Permanent J-Code Effective April 1, 2023 ~ ~ Recent Positive CHMP Opinion in EU Recommending Approval of PEDMARQSI™ ~ ~ Company to Host Conference Call Today, Thursday, May 11 at 8:30 a.m.

RHEA-AI

neutral

05/08/23 6:15 AM

Nasdaq : FENC

conferencesearningslow float

Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2023 financial results before the opening of the U.S. financial

RHEA-AI

neutral

03/31/23 8:03 AM

Nasdaq : FENC

low float

Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

~ First Therapy Recommended for Approval in the European Union for Reducing the Risk of Cisplatin-induced Hearing Loss (Ototoxicity) in Pediatric Patients with Localized, Non-metastatic Solid Tumors~ ~ Positive CHMP Opinion Based on Clinical Results Demonstrating Prevention of Ototoxicity and a

RHEA-AI

neutral

03/30/23 5:55 AM

Nasdaq : FENC

earningslow float

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX:

RHEA-AI

positive

01/31/23 6:00 AM

Nasdaq : FENC

low float

Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA

~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ ~ Orphan Drug Exclusivity Provides Seven Years of Market Exclusivity for PEDMARK® from its FDA Approval on

RHEA-AI

very positive

FENC Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitehttp://fennecpharma.com/
Security nameFennec Pharmaceuticals Inc
SectorManufacturing
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
CountryUS

About Fennec Pharmaceuticals Inc

fennec pharmaceuticals inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the united states. its lead product pedmark, a formulation of sodium thiosulfate, which has completed the phase iii clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. the company was formerly known as adherex technologies inc. and changed its name to fennec pharmaceuticals inc. in september 2014. fennec pharmaceuticals inc. was founded in 1996 and is based in research triangle park, north carolina.